BeiGene to Announce First Quarter 2025 Financial Results on May 7
BeiGene (NASDAQ: ONC) announced it will release its first quarter 2025 financial results on Wednesday, May 7, 2025, before market open. The company, which plans to change its name to BeOne Medicines , will host a live management webcast at 8:00 a.m. ET on the same day.
Participants can access the webcast through the investors section of BeiGene's website and are advised to register 15 minutes before the scheduled start. The webcast recording will be archived on the company's website.
BeiGene (NASDAQ: ONC) ha annunciato che pubblicherà i suoi risultati finanziari del primo trimestre 2025 mercoledì 7 maggio 2025, prima dell'apertura dei mercati. L'azienda, che ha in programma di cambiare nome in BeOne Medicines, terrà una webcast dal vivo con il management alle 8:00 ET dello stesso giorno.
I partecipanti potranno accedere alla webcast attraverso la sezione investitori del sito web di BeiGene e sono invitati a registrarsi 15 minuti prima dell'inizio previsto. La registrazione della webcast sarà archiviata sul sito dell'azienda.
BeiGene (NASDAQ: ONC) anunció que publicará sus resultados financieros del primer trimestre de 2025 el miércoles 7 de mayo de 2025, antes de la apertura del mercado. La compañía, que planea cambiar su nombre a BeOne Medicines, realizará una transmisión en vivo con la dirección a las 8:00 a.m. ET del mismo día.
Los participantes podrán acceder a la transmisión a través de la sección de inversores en el sitio web de BeiGene y se recomienda registrarse 15 minutos antes del inicio programado. La grabación de la transmisión estará archivada en el sitio web de la empresa.
BeiGene (NASDAQ: ONC)은 2025년 5월 7일 수요일, 시장 개장 전인 오전 8시(동부시간)에 2025년 1분기 재무 실적을 발표할 예정이라고 밝혔습니다. 회사는 BeOne Medicines로 사명을 변경할 계획이며, 같은 날 오전 8시(동부시간)에 경영진의 라이브 웹캐스트를 진행합니다.
참석자들은 BeiGene 웹사이트의 투자자 섹션을 통해 웹캐스트에 접속할 수 있으며, 예정된 시작 15분 전에 등록할 것을 권장합니다. 웹캐스트 녹화본은 회사 웹사이트에 아카이브됩니다.
BeiGene (NASDAQ : ONC) a annoncé qu'elle publiera ses résultats financiers du premier trimestre 2025 le mercredi 7 mai 2025, avant l'ouverture des marchés. La société, qui prévoit de changer de nom pour BeOne Medicines, organisera une webdiffusion en direct avec la direction à 8h00 ET le même jour.
Les participants pourront accéder à la webdiffusion via la section investisseurs du site web de BeiGene et sont invités à s'inscrire 15 minutes avant le début prévu. L'enregistrement de la webdiffusion sera archivé sur le site de l'entreprise.
BeiGene (NASDAQ: ONC) gab bekannt, dass es seine Finanzergebnisse für das erste Quartal 2025 am Mittwoch, den 7. Mai 2025, vor Markteröffnung veröffentlichen wird. Das Unternehmen, das plant, seinen Namen in BeOne Medicines zu ändern, wird am selben Tag um 8:00 Uhr ET eine Live-Webcast mit dem Management veranstalten.
Teilnehmer können über den Investor-Bereich auf der Website von BeiGene auf den Webcast zugreifen und werden gebeten, sich 15 Minuten vor Beginn zu registrieren. Die Aufzeichnung des Webcasts wird auf der Unternehmenswebsite archiviert.
- None.
- None.
The conference call will be webcast live and a link to the webcast can be accessed from the investors section of the Company’s website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website.
About BeiGene
BeiGene, which plans to change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 11,000 colleagues spans six continents. To learn more about BeiGene, please visit www.beigene.com.
Forward-Looking Statements
This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene's plans, commitments, aspirations and goals related to BeiGene’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeiGene’s most recent periodic report filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250417063044/en/
Investors:
Liza Heapes
+1 857-302-5663
ir@beigene.com
Media:
Kyle Blankenship
+1 667-351-5176
media@beigene.com
Source: BeiGene, Ltd.
FAQ
When will BeiGene (ONC) release Q1 2025 earnings?
What time is BeiGene's (ONC) Q1 2025 earnings call?
Why is BeiGene (ONC) changing its name?
How can investors access BeiGene's (ONC) Q1 2025 earnings webcast?
